Health News Archive - May 14, 2009
SEATTLE, May 14 /PRNewswire-FirstCall/ - Oncothyreon Inc.
CORAL GABLES, Fla., May 14 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported financial results for the first quarter ended March 31, 2009.
By 2013, over 685,000 PCI and 165,000 CABG procedures will be performed, according to Millennium Research Group WALTHAM, Mass., May 14 /PRNewswire/ -- According to two new Millennium Research Group (MRG) reports, emerging clinical data and innovations in device technology will shift the balance between percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) procedures for unique subgroups with coronary artery disease through 2013.
LAKE FOREST, Ill., May 14 /PRNewswire/ -- - Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced the launch of Enlon(R) (edrophonium chloride injection, USP) and Enlon-Plus(R) (edrophonium chloride, USP and atropine sulfate, USP) Injection.
New manufacturing facility opens with substantially increased capacity for continued growth TORONTO, May 14 /PRNewswire-FirstCall/ - Microbix Biosystems Inc.
- Phase 3 CAPACITY results poster presentation Sunday, May 17, 8:15 a.m. PDT - - Phase 3 CAPACITY results oral presentation, Tuesday, May 19, 3:35 p.m. PDT - - Conference call and webcast Tuesday, May 19, 6 p.m. PDT - BRISBANE, Calif., May 14 /PRNewswire-FirstCall/ -- InterMune, Inc.
Company Launches its MedSync(TM) Software During National Press Event at the National Press Club WASHINGTON, May 14 /PRNewswire-FirstCall/ -- Connectyx Technologies Holdings Group, Inc.
DENVER, May 14 /PRNewswire-FirstCall/ -- Birner Dental Management Services, Inc. (Nasdaq: BDMS), operators of PERFECT TEETH dental practices, announced results for the quarter ended March 31, 2009. Total dental group practice revenue increased $87,000, or 0.6%, to $15.3 million.
A portion of sales will be donated to the Stem for Life Foundation NEW YORK, May 14 /PRNewswire-FirstCall/ -- NeoStem, Inc.
Comprehensive Phase 2 Program Combines Histology, Biomarkers and Non-Invasive Imaging to Demonstrate Mechanism of Action and Positive Impact on Vascular Inflammation SAN FRANCISCO, May 14 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc.